CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
9.64
+0.24 (2.55%)
At close: Aug 13, 2025, 4:00 PM
9.30
-0.34 (-3.53%)
Pre-market: Aug 14, 2025, 9:06 AM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2024. The number of employees increased by 7 or 87.50% compared to the previous year.
Employees
15
Change (1Y)
7
Growth (1Y)
87.50%
Revenue / Employee
$518,465
Profits / Employee
-$1,507,460
Market Cap
89.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRVO News
- 16 days ago - CervoMed's Dementia Data Show Slowed Disease Progression - Benzinga
- 17 days ago - CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration - GlobeNewsWire
- 5 weeks ago - CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025 - GlobeNewsWire
- 3 months ago - CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 5 months ago - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - GlobeNewsWire
- 5 months ago - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
- 5 months ago - CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - GlobeNewsWire